Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6255 in Advanced Solid Tumors
NCT07870278Phase 1Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2026
- Primary completion
- Jul 2031
01
Overview
Phase 1, open-label trial of MK-6255 in ovarian cancer and endometrial cancer (EC) (2 arms), sponsored by Merck & Co. Primary endpoints: Dose-limiting Toxicity at 21 days, Adverse Events at 56 months and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
MK-6255
03
Conditions
ovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT07870278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870278.